Nicox (ALCOX.PA) Market Update – 22 April 2026
- Current price: EUR 0.30 (as of 05:41 AM CET).
- Price change: +2.02 % over the last 24 hours.
- Volume: EUR 88.8 k traded in the past 24 hours.
- Shares outstanding: 88.8 million.
- Market capitalization: EUR 25.1 million.
- Historical performance: Down 11.27 % since the end of the previous month.
- 200‑day simple moving average: EUR 0.38.
- 52‑week high: EUR 0.57 (recorded 25 February 2026).
- 52‑week low: EUR 0.28 (recorded 20 October 2026).
Peer Performance (Last 24 Hours)
| Stock | Symbol | Price Change | Current Price | Market Cap (EUR) | P/E (where applicable) |
|---|---|---|---|---|---|
| Hipay | ALHYP.PA | 0.00 % | EUR 4.30 | 26.8 m | 6.52 |
| Europacorp | ALECP.PA | –1.26 % | EUR 0.24 | 29.8 m | – |
| Uniti | ALUNT.PA | 0.00 % | EUR 1.02 | 25.9 m | 2,727.27 |
| Canal+ | CAN.L | +0.83 % | GBX 242 | 3.2 bn | – |
| Media | Media | 0.00 % | EUR 9.89 | 26 m | – |
Company Profile – Nicox S.A.
- Headquarters: Valbonne, France.
- Founded: 1996.
- Industry: Health‑care biotechnology; focus on ophthalmic therapies.
- Research & Development:
- Vyzulta™ – intraocular pressure‑lowering treatment.
- NCX 470 – nitric‑oxide donor for glaucoma.
- Stand‑alone NO donors for other ophthalmic diseases.
- ZERVIATE – cetirizine eye drop for allergic conjunctivitis.
- NCX 4280 – solution for morning ocular congestion.
- NCX 4251 – fluticasone propionate for blepharitis.
- Strategic Partnerships: Bausch + Lomb, AstraZeneca, Merck, Pfizer, Ironwood Pharmaceuticals, Inc., and Novaliq GmbH.
- Public Listing: NYSE and Euronext Paris.
For additional details, visit www.nicox.com .
